- KNMD has a number of collaborations but no clinical trials to-date.
- KNMD is a revenue-generating health technology company that has developed a proprietary biomarker platform technology with numerous applications in drug development and medical diagnostics.
- Research agreements with pharmaceutical and biotechnology companies include Glaxo Group Limited, or GSK, Pfizer, and Bristol Myers Squibb.
- KNMD, developer of a biomarker platform technology, used in medical diagnostics and drug development, plans to raise $31.5 million in its upcoming IPO.
- KNMD is losing money at an accelerating rate, and is scarcely generating revenue despite many powerful partnerships.
- We plan to avoid this IPO and suggest investors consider doing so, as well.
There are no Transcripts on KNMD.
There are no News articles on KNMD.
We currently have no Breaking News on this stock.